Ventus Therapeutics

We had such a wonderful time celebrating the grand opening of our new site in Montreal last week! This marked a special moment as we fondly remembered where #Ventus Therapeutics started just 5 years ago in Montreal and got to celebrate the growth and success that led to our move into our beautiful new home. The event was made even more special with the presence of our dedicated Ventus employees, their families, our supportive investors, esteemed board members, and our friends from the Montreal biotech community. Thank you to everyone who joined us. We look forward to all of the collaboration that will come in this space and working together toward discovering and designing novel #smallmoleculetherapeutics using our ML-enabled computational chemistry platform, ReSOLVE™. Read more: https://lnkd.in/eK6bHEA7

Finding cures for diseases like Parkinson’s means leaving no stone unturned. On the verge of developing a new kind of molecule to help combat the neurodegenerative condition, Ventus Therapeutics screened a documentary film about Parkinson’s for the entire company. The next day they invited a specialist to speak to everyone. On the third day, a patient with a severe form of Parkinson's shared his experience living with the disease. All three events were mandatory for employees, whether they were an accountant or a chemist. What was the impact? “Try telling someone at the company today that we’re giving up on Parkinson’s,” says CEO Marcelo Bigal. “They’re going to fight for it. The accountant is going to find money for Parkinson’s. This is our disease. Those events touched everyone at the company. They changed us.” Read our full Q&A with Bigal that spotlights how Ventus’s approach to drug discovery is unquestionably people-centered. https://lnkd.in/gveCgDTF #biotech #medicine #innovation

For our next #Employee Spotlight, we’re featuring Vasiliy Sysoev! Vasiliy is a Senior Scientist at Ventus. Today, he shares with us why science is his passion. #VentusTx

“ …we know exactly who we serve. We don't serve the target, we don't serve the protein, we don't serve the platform. We serve the patients who are struggling with a disease,” said Ventus CEO, Marcelo Bigal, M.D., Ph.D. in a recent interview with SoftBank Group Corp.’s Sōzō Insights Program. Marcelo talks about our people-centric operations in an open Q&A, diving deeper into his leadership style that’s driven our pipeline and company success for the past five years. Read more: https://lnkd.in/eSySgaVg

For our next #Employee Spotlight, we’re featuring Loraine Warner! Loraine is the Head of Clinical Operations at Ventus. Today, she shares with us what inspired her to pursue science! #VentusTx

Ventus’ Head of Platform Technologies, Jason Burch, appeared on Bloomberg Intelligence’s Tech Disruptors podcast to discuss our unique approach to discovering and designing novel small molecule therapeutics with our ReSOLVE drug discovery platform.    Together with SoftBank Investment Advisers Investment Advisors’ John Cassidy, the two cover opportunities in health tech, #AI, platform technologies, and more pressing issues in #lifesciences and #healthcare with hosts Sam Fazeli and Mandeep Singh, CFA. Listen now: https://lnkd.in/ed4a5CkS

Ventus’ Chief Scientific Officer Michael Crackower, Ph.D., will take the panel stage tomorrow afternoon at Northeastern University College of Science’s Barnett Institute 50th Anniversary and Karger Medal Celebration. Led by Laurent Audoly, Ph.D., Senior Advisor to the Institute for Experiential AI at Northeastern, the panel will cover all things #drugdiscovery and #AI, exploring the latest advancements in the AI field and its potential use in healthcare.

We just announced that our partner, Novo Nordisk, has successfully dosed the first participant in a Phase 1 clinical study for NNC6022-0001, an oral NLRP3 inhibitor, making it the third Ventus-discovered compound to enter the clinic in the last nine months. Congratulations to Novo Nordisk on reaching this important clinical milestone.  https://lnkd.in/euKVBUnZ

For our next #Employee Spotlight, we’re featuring Alex Skeldon! Alex is a Principal Scientist on our Immunology team. Alex shares with us what inspired him to pursue science! #VentusTx

Today, we're happy to share Phase 1 clinical trial results of VENT-02, our novel, orally administered, brain-penetrant NLRP3 inhibitor. VENT-02 demonstrated a broad therapeutic index and complete target coverage with no dose-limiting toxicities or serious adverse events observed.   We look forward to initiating clinical trials in patients with CNS diseases beginning in the second half of 2024. Discover more below. https://lnkd.in/em68hNxG